Physician profile
Daniel M Ostrowski
NPI 1740648922
$25,060.40
in general payments reported to CMS, 2019-2025
56 companies · $4,882 in 2025
The $4,882 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,823 · 2022: $3,428 · 2023: $4,120 · 2024: $6,807 · 2025: $4,882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,809.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,292.59 | 2021-2025 | |
| Emd Serono, INC. | $2,418.23 | 2021-2025 | Mavenclad, Mavenclad |
| Teva Pharmaceuticals USA, INC. | $2,136.59 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Biogen, INC. | $1,784.07 | 2021-2025 | Vumerity, Leqembi, Tysabri |
| Neurocrine Biosciences, INC. | $992.90 | 2021-2025 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $974.45 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Biohaven Pharmaceuticals, INC. | $969.55 | 2021 | |
| Ani Pharmaceuticals, INC. | $810.22 | 2022-2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $549.53 | 2024-2025 | Auvelity, Symbravo, Sunosi |
| Celgene Corporation | $546.43 | 2021-2025 | Zeposia |
| Vanda Pharmaceuticals INC. | $499.91 | 2024-2025 | Ponvory, Fanapt |
| Janssen Pharmaceuticals, INC | $497.43 | 2021-2023 | Ponvory |
| Genentech USA, INC. | $477.14 | 2023-2025 | Ocrevus Zunovo, Ocrevus |
| Tg Therapeutics, INC. | $462.88 | 2023-2025 | |
| Amgen INC. | $456.77 | 2024-2025 | Uplizna |
Show all 56 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $455.73 | 2021-2025 | Briviact, Nayzilam |
| Argenx US, INC. | $451.55 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $450.95 | 2021-2024 | Ultomiris |
| Sk Life Science, INC. | $441.78 | 2021-2025 | |
| Lilly USA, LLC | $437.35 | 2021-2025 | Kisunla |
| Scilex Pharmaceuticals INC. | $399.82 | 2021-2025 | Ztlido |
| Genentech, INC. | $380.41 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Lundbeck LLC | $347.26 | 2021-2025 | Vyepti, Rexulti |
| Horizon Therapeutics Plc | $338.09 | 2022-2023 | Uplizna |
| E.R. Squibb & Sons, L.L.C. | $318.64 | 2021-2025 | Cobenfy, Zeposia |
| Kyowa Kirin, INC. | $294.30 | 2021-2024 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $237.25 | 2022 | |
| Corium, LLC | $230.94 | 2023-2024 | Azstarys, Adlarity |
| Genzyme Corporation | $230.45 | 2021-2025 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $188.78 | 2024 | |
| Sumitomo Pharma America, INC. | $188.72 | 2023-2024 | Aptiom |
| Sunovion Pharmaceuticals INC. | $187.07 | 2022 | |
| Impel Pharmaceuticals INC. | $179.19 | 2023 | Trudhesa |
| Ipsen Biopharmaceuticals, INC | $159.19 | 2024-2025 | Dysport |
| Inspire Medical Systems, INC. | $147.09 | 2025 | Inspire |
| Acadia Pharmaceuticals INC | $137.94 | 2024-2025 | Nuplazid |
| Mallinckrodt Hospital Products INC. | $133.19 | 2022-2025 | Acthar |
| Sage Therapeutics, LLC | $115.48 | 2024 | |
| Mylan Specialty L.P. | $109.41 | 2023 | Yupelri |
| Almatica Pharma LLC | $94.10 | 2021-2022 | |
| Pfizer INC. | $90.94 | 2023-2024 | |
| Eisai INC. | $78.06 | 2021-2023 | |
| Neurelis, INC. | $67.90 | 2021-2023 | Valtoco |
| Octapharma USA, INC. | $43.51 | 2024-2025 | Panzyga |
| Cycle Pharmaceuticals INC | $42.44 | 2025 | Tascenso Odt, Bafiertam |
| Merz Pharmaceuticals, LLC | $40.61 | 2024 | Xeomin |
| Tonix Medicines, INC. | $22.59 | 2025 | Tonmya |
| Vertex Pharmaceuticals Incorporated | $21.26 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.02 | 2025 | Amvuttra |
| Amneal Pharmaceuticals LLC | $19.93 | 2025 | Brekiya |
| Ge Healthcare | $16.35 | 2025 | |
| Arbor Pharmaceuticals, INC. | $16.00 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $15.17 | 2021 | |
| Upsher-Smith Laboratories LLC | $15.00 | 2021 | |
| Avion Pharmaceuticals | $14.75 | 2023 | Dhivy |
| Allergan, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.